ArticleOncoTargets and therapy2019
Knockdown of lncRNA HOXA-AS2 Inhibits Viability, Migration and Invasion of Osteosarcoma Cells by miR-124-3p/E2F3.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- HOXA-AS2 may predict the prognosis of solid tumors among Chinese patients: A meta-analysis and bioinformatic analysis.Frontiers in oncology · 2022Pooled it
- HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis.Frontiers in genetics · 2022Pooled it
- The HOXA gene cluster: a critical regulator in bone-related disorders.Annals of medicine · 2026Review
- Universal penalized regression (Elastic-net) model with differentially methylated promoters for oral cancer prediction.European journal of medical research · 2024Article
- LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis.Oncology letters · 2024Article
- Role of HOXA1-4 in the development of genetic and malignant diseases.Biomarker research · 2024Review
- Article
- Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.International journal of molecular sciences · 2023Review
- Assessment of the prognostic and clinicopathological significance of HOXA-AS2 in human cancers: a systematic review and meta-analysis.Translational cancer research · 2023Article
- EBF1-mediated up-regulation of lncRNA FGD5-AS1 facilitates osteosarcoma progression by regulating miR-124-3p/G3BP2 axis as a ceRNA.Journal of orthopaedic surgery and research · 2022Article
- HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis.Cell death & disease · 2022Article
- lncRNA DARS-AS1 Promoted Osteosarcoma Progression through Regulating miR-532-3p/CCR7.Disease markers · 2022Article
- Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression.Frontiers in cell and developmental biology · 2022Review
- miR-1270 enhances the proliferation, migration, and invasion of osteosarcoma <em>via</em> targeting cingulin.European journal of histochemistry : EJH · 2021Article
- Long noncoding RNA MAPKAPK5-AS1 promoted lipopolysaccharide-induced inflammatory damage in the myocardium by sponging microRNA-124-3p/E2F3.Molecular medicine (Cambridge, Mass.) · 2021Article
- Long-non-coding RNA RUSC1-AS1 accelerates osteosarcoma development by miR-101-3p-mediated Notch1 signalling pathway.Journal of bone oncology · 2021Article
- CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through β-catenin.Cell death & disease · 2021Article
- Circular RNA CDR1as promotes tumor progression by regulating miR-432-5p/E2F3 axis in pancreatic cancer.Cancer cell international · 2021Article
- LncRNA HOXA-AS2 promotes glioblastoma carcinogenesis by targeting miR-885-5p/RBBP4 axis.Cancer cell international · 2021Article
- A Pan-Cancer Landscape of HOX-Related lncRNAs and Their Association With Prognosis and Tumor Microenvironment.Frontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS) is one of the most frequent bone malignancies. Long noncoding RNAs (lncRNAs) have been revealed to participate in many cancers, including OS. This study aimed to explore the biological function of lncRNA homeobox A cluster antisense RNA2 (HOXA-AS2) and its potential mechanism in OS progression.
methodsTwenty-seven OS patients were recruited for this study. U2OS and MG-63 cells were cultured for in vitro analyses. The levels of HOXA-AS2, microRNA-124-3p (miR-124-3p) and E2F transcription factor 3 (E2F3) were measured by quantitative real-time polymerase chain reaction or Western blot. OS progression was investigated by cell viability, migration and invasion using cell counting kit-8 or trans-well assay. The interaction among HOXA-AS2, miR-124-3p and E2F3 was explored by bioinformatics analysis, luciferase reporter assay, RNA immunoprecipitation and biotinylated RNA pull-down. Xenograft model was established by injecting U2OS cells into nude mice.
resultsHOXA-AS2 expression was increased in OS tissues and cells and associated with poor survival of patients. Knockdown of HOXA-AS2 inhibited cell viability, migration and invasion in OS cells. miR-124-3p could bind with HOXA-AS2 and its deficiency reversed the suppressive role of HOXA-AS2 knockdown. Moreover, E2F3 acted as a target of miR-124-3p and positively regulated by HOXA-AS2. Silence of E2F3 suppressed OS progression, which was abolished by miR-124-3p exhaustion. Interference of HOXA-AS2 attenuated U2OS xenograft tumor growth via upregulating miR-124-3p and downregulating E2F3.
conclusionHOXA-AS2 silence impeded OS progression possibly by functioning as a decoy of miR-124-3p to target E2F3, indicating novel evidence of HOXA-AS2 as a promising therapeutic target of OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.